healthcare

We Haven’t Scratched the Surface of Weight-Loss Drug Advances

Orforglipron is an oral drug from Eli Lilly that’s in trial stage. The New York Times reports that in a trial of over 500 patients, those “who took the highest dose lost an average of around 16 pounds after nine months.” The Times added that roughly “two-thirds of people who took the drug also saw their blood sugar […]

We Haven’t Scratched the Surface of Weight-Loss Drug Advances Read More »

On the Doorstep of Pharmaceutical Cures That Will Boggle the Mind

“There is a ‘treasure trove of medicines that could be used for so many other diseases.’” Those are the words of Donald C. Lo, former head of therapeutic development at the National Center for Advancing Translational Sciences, as told to Kate Morgan of the New York Times. What an exciting statement, one that indicates doctors and scientists

On the Doorstep of Pharmaceutical Cures That Will Boggle the Mind Read More »

Will President Trump’s AI Crusade Save Rural Hospitals?

President Trump declared that the U.S. will be “the world capital of artificial intelligence” at the World Economic Forum in Davos, Switzerland. Trump’s commitment carries significant weight, given that he has already repealed a Biden-era executive order that aimed to monitor and regulate AI, which carried the risk of slowing our development of this technology compared to foreign competitors. President

Will President Trump’s AI Crusade Save Rural Hospitals? Read More »

The Real Danger of Artificial Intelligence Is Delay

The New York Times recently reported on the latest calls for more government regulation—even on an international scale—over the field of artificial intelligence due to perceived risks. Such commentary has seemingly become ubiquitous both in the media and from policymakers in D.C. who, while well-intentioned, seem to owe reflection to the broader picture of why developing

The Real Danger of Artificial Intelligence Is Delay Read More »

Scroll to Top